S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
TSE:CMED

CanniMed Therapeutics Stock Forecast, Price & News

C$27.00
-1.50 (-5.26%)
(As of 05/1/2018)
Add
Compare
Today's Range
C$27.00
C$28.50
50-Day Range
N/A
52-Week Range
C$7.32
C$46.00
Volume
52,208 shs
Average Volume
387,394 shs
Market Capitalization
C$668.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CMED News and Ratings via Email

Sign-up to receive the latest news and ratings for CanniMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


CanniMed Therapeutics logo

About CanniMed Therapeutics

CanniMed Therapeutics Inc. operates as a plant biopharmaceutical company that specializes in medical cannabis. The company cultivates and sells pharmaceutical-grade cannabis products in dried herbal and oil forms for Canadian patients. It also offers herbal cannabis and cannabis oil; and vaporizers, consumable vaporizer accessories, and herb mills. In addition, the company offers a plant biotechnology research and product development program that focuses on the production of plant-based materials for pharmaceutical, agricultural, and environmental applications. CanniMed Therapeutics Inc. was founded in 1988 and is based in Saskatoon, Canada. As of March 28, 2018, CanniMed Therapeutics Inc. operates as a subsidiary of Aurora Cannabis Inc.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Electronic Computer Manufacturing
Sub-Industry
Cannabis
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
C$668.44 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












CanniMed Therapeutics (TSE:CMED) Frequently Asked Questions

How has CanniMed Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

CanniMed Therapeutics' stock was trading at C$27.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CMED shares have increased by 0.0% and is now trading at C$27.00.
View which stocks have been most impacted by COVID-19
.

Who are CanniMed Therapeutics' key executives?

CanniMed Therapeutics' management team includes the following people:
  • Mr. Andre Jerome, CEO & Director
  • Mr. John Lewis Knowles BComm., CPA, C.A., CFO, Corp. Sec. & Non-Independent Director (Age 63)
  • Mr. Howard Harkness, VP of Marketing & Sales

What other stocks do shareholders of CanniMed Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CanniMed Therapeutics investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), Smith & Nephew (SNN), Hydropothecary (THCX), CannTrust (CTST), Cronos Group (CRON), Cronos Group (MJN), CannaRoyalty (CNNRF), KushCo (KSHB) and Leaf Mobile (LEAF).

What is CanniMed Therapeutics' stock symbol?

CanniMed Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CMED."

How do I buy shares of CanniMed Therapeutics?

Shares of CMED and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is CanniMed Therapeutics' stock price today?

One share of CMED stock can currently be purchased for approximately C$27.00.

How much money does CanniMed Therapeutics make?

CanniMed Therapeutics has a market capitalization of C$668.44 million.

How many employees does CanniMed Therapeutics have?

CanniMed Therapeutics employs 147,000 workers across the globe.

What is CanniMed Therapeutics' official website?

The official website for CanniMed Therapeutics is www.cannimedtherapeutics.com.

Where are CanniMed Therapeutics' headquarters?

How can I contact CanniMed Therapeutics?

CanniMed Therapeutics' mailing address is 1 Plant Technology Road, Box 19A, RR #5, SASKATOON, SK S7K 3J8, Canada. The company can be reached via phone at +1-306-9751207.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.